MedTrace Logo

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

NCT00131677 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2014-03-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine safety and tolerability of daily tenofovir use in HIV-uninfected men.

Conditions

  • HIV Infection

Interventions

DRUG

tenofovir disoproxil fumarate

study product taken daily

DRUG

placebo

study product taken daily

Sponsors & Collaborators

Principal Investigators

  • Kata L Chillag, PhD · Centers for Disease Control and Prevention

  • Lisa A Grohskopf, MD, MPH · Centers for Disease Control and Prevention

  • Susan Buchbinder, MD · San Francisco Dept. of Public Health

  • Melanie Thompson, MD · AIDS Research Consortium of Atlanta

  • Kenneth H. Mayer, MD · Fenway Community Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00131677 on ClinicalTrials.gov